Psych Vivas · Consultation-liaison — hepatic encephalopathy and advanced transplant psychiatry
Hepatic encephalopathy and advanced transplant psychiatry — structured clinical viva
Fellowship viva spanning HE neuropsychiatry and advanced liver transplant psychosocial evaluation.
On this page & tools
Target exams
Interpretation
Reveal interpretation
Station A — HE mislabeled as primary bipolar. Open with safety and medical ownership: this is type C HE until proven otherwise — asterixis, fluctuation, cirrhosis context. Grade using West Haven language; list precipitants including the benzodiazepine just given; stop unnecessary sedatives; lactulose pathway; consider rifaximin if this is recurrent disease after remission.[1][2][3] Ammonia is supportive only. Capacity: decision-specific; reassess when lucid; emergency necessity if incapacity and serious harm.[6] If valproate appears on the chart with rising ammonia, treat as possible VPA hyperammonaemic encephalopathy and stop VPA.[7] Do not launch a lifelong bipolar label from a single organic episode.
Station B — Listing MDT. Role clarity: psychiatry contributes structured risk and optimisation, not unilateral veto theatre. Use SIPAT/ISHLT-style domains: psychopathology (depression treatment, suicide risk), substance recovery engagement and monitoring, social support, adherence (DNA pattern as modifiable signal), readiness/health literacy, and capacity for transplant consent after material disclosure.[4][6] Cite Dew: depression/anxiety associate with worse post-transplant outcomes — treat as modifiable medical risk.[5] Absolute vs relative barriers are programme-defined; do not invent a universal six-month abstinence statute; Mathurin early LT for select severe AH is the classic counter-example that selection, not slogans, matter.[8] Communication script: domains assessed, optimisations underway, residual risks, monitoring plan, timestamped capacity statement — never “psych clear.”
Key points
- HE clinical diagnosis; West Haven / covert–overt language
- Lactulose cornerstone; rifaximin for recurrence (Bass)
- Benzodiazepines raise HE risk — not first-line agitation care in cirrhosis
- SIPAT structures risk; MDT lists
- Capacity fluctuates with HE — reassess
- Depression after transplant is an outcome risk (Dew)
- VPA hyperammonaemia: stop the drug
- No invented statutes or universal abstinence rules
References
- [1]Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Hepatology, 2014.PMID 25042402
- [2]Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy N Engl J Med, 2010.PMID 20335583
- [3]Grønbæk L, Watson H, Vilstrup H, et al. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites United European Gastroenterol J, 2018.PMID 29774154
- [4]Maldonado JR, Dubois HC, David EE, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates Psychosomatics, 2012.PMID 22424160
- [5]Dew MA, Rosenberger EM, Myaskovsky L, et al. Depression and Anxiety as Risk Factors for Morbidity and Mortality After Organ Transplantation: A Systematic Review and Meta-Analysis Transplantation, 2015.PMID 26492128
- [6]Appelbaum PS Clinical practice. Assessment of patients' competence to consent to treatment N Engl J Med, 2007.PMID 17978292
- [7]Segura-Bruna N, Rodriguez-Campello A, Puente V, et al. Valproate-induced hyperammonemic encephalopathy Acta Neurol Scand, 2006.PMID 16774619
- [8]Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis N Engl J Med, 2011.PMID 22070476